After falling off their perch in the last few months of 2024, European healthcare stocks head into a new year facing the jeopardy of US politics and high-stakes trial results for new drugs.
Key for investors will be clarity on American healthcare policy after president-elect Donald Trump’s nomination of health officials, including a prominent vaccine skeptic, sparked a selloff that reduced the sector from a top performer to middle-of-the-pack mediocrity.